The primary safety end point was PLATO major bleeding. DM +/ CKD + patients had a higher incidence of the primary end point compared with DM -/ CKD - patients ( ...

Mar 12, 2019 · Acute coronary syndrome patients with diabetes mellitus and chronic kidney disease are at markedly increased risk for long‐term atherothrombotic events.

Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol.

... Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary. Syndromes: Insights From the PLATO Trial ...

Mar 13, 2019 · The primary safety end point was PLATO major bleeding. DM+/CKD+ patients had a higher incidence of the primary end point compared with DM−/CKD− ...

Oct 4, 2019 · The primary safety end point was PLATO major bleeding. DM+/CKD+ patients had a higher incidence of the primary end point compared with DM-/CKD- ...

Missing: P2Y12 | Show results with:P2Y12

Missing: Antagonist | Show results with:Antagonist

Among patients with diabetes mellitus treated with clopidogrel, impaired renal function was associated with increased maximum platelet aggregation.

The risk of all-cause death and cardiac death was increased by about 2-fold in the presence of CKD or DM alone and by about 5- and 6-fold, respectively, in ...